Dorzolamide/Timolol — Discount Pricing

About Dorzolamide/Timolol

Dorzolamide timolol is a common and effective medication prescribed to help manage glaucoma and ocular hypertension. If you're relying on this important eye drop to protect your vision, you know the cost can add up. TheDrugClub is here to make your treatment more affordable, offering significant savings and convenience.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Dorzolamide/Timolol is approved for (FDA label)

Dorzolamide hydrochloride and timolol maleate ophthalmic solution is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers (failed to achieve target IOP determined after multiple measurements over time).

Source: Read the full FDA label on DailyMed. Label effective date: August 13, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Dorzolamide/Timolol (FDA label)

Ophthalmic solution containing dorzolamide 20 mg/mL (2%) equivalent to 22.26 mg/mL of dorzolamide hydrochloride USP, and timolol 5 mg/mL (0.5%) equivalent to 6.83 mg/mL of timolol maleate USP. Ophthalmic solution containing dorzolamide 20 mg/mL (2%) and timolol 5 mg/mL (0.5%). (3)

Source: FDA prescribing information (DailyMed). Set ID: 2d5dcaa5-97ee-40c3-aa29-fcfb91fb78e1. SPL document ID: f322a8a9-c2e2-4e7a-82b8-070c88e763b8. Label effective date: August 13, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Dorzolamide/Timolol (FDA label)

The most frequently reported adverse reactions were taste perversion (bitter, sour, or unusual taste) or ocular burning and/or stinging in up to 30% of patients. Conjunctival hyperemia, blurred vision, superficial punctate keratitis or eye itching were reported between 5 to 15% of patients. (6) To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc., at 1-866-­850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 2d5dcaa5-97ee-40c3-aa29-fcfb91fb78e1. SPL document ID: f322a8a9-c2e2-4e7a-82b8-070c88e763b8. Label effective date: August 13, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Dorzolamide/Timolol (FDA label)

Dorzolamide hydrochloride and timolol maleate is contraindicated in patients with: Bronchial asthma or a history of bronchial asthma, severe chronic obstructive pulmonary disease. (4.1) Sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, cardiogenic shock. (4.2) Hypersensitivity to any component of this product. (4.3 , 5.3) 4.1 Asthma, COPD Dorzolamide hydrochloride and timolol maleate ophthalmic solution is contraindicated in patients with bronchial asthma, a history of bronchial asthma, or severe chronic obstructive pulmonary disease [see Warnings and Precautions (5.1) ]. 4.2 Sinus Bradycardia, AV Block, Cardiac Failure, Cardiogenic Shock Dorzolamide hydrochloride and timolol maleate ophthalmic solution is contraindicated in patients with sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, and cardiogenic shock [see Warnings and Precautions (5.2) ]. 4.3 Hypersensitivity Dorzolamide hydrochloride and timolol maleate ophthalmic solution is contraindicated in patients who are hypersensitive to any component of this product [see Warnings and Precautions (5.3) ] .

Source: FDA prescribing information (DailyMed). Set ID: 2d5dcaa5-97ee-40c3-aa29-fcfb91fb78e1. SPL document ID: f322a8a9-c2e2-4e7a-82b8-070c88e763b8. Label effective date: August 13, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Dorzolamide/Timolol (FDA label)

Potentiation of Respiratory Reactions Including Asthma (5.1) Cardiac Failure (5.2) Sulfonamide Hypersensitivity (5.3) Obstructive Pulmonary Disease (5.4) Increased Reactivity to Allergens (5.5) Potentiation of Muscle Weakness (5.6) Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus (5.7) Masking of Thyrotoxicosis (5.8) Renal and Hepatic Impairment (5.9) Impairment of Beta-Adrenergically Mediated Reflexes During Surgery (5.10) 5.1 Potentiation of Respiratory Reactions Including Asthma Dorzolamide hydrochloride and timolol maleate ophthalmic solution contains timolol maleate, a beta-adrenergic blocking agent; and although administered topically, is absorbed systemically. Therefore, the same types of adverse reactions that are attributable to systemic administration of beta-adrenergic blocking agents may occur with topical administration.

Source: FDA prescribing information (DailyMed). Set ID: 2d5dcaa5-97ee-40c3-aa29-fcfb91fb78e1. SPL document ID: f322a8a9-c2e2-4e7a-82b8-070c88e763b8. Label effective date: August 13, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.